Flunitrazepam

Use

In countries where this drug is used, it is used for treatment of severe cases of sleeping problems, and in some countries as a preanesthetic agent.

It has also been administered as a concurrent dose for patients that are taking ketamine. Flunitrazepam lowers the side effects of the anesthetic (ketamine), resulting in less confusion in awakening states, less negative influence on pulse rate, and fewer fluctuations in blood pressure.

Adverse effects

Adverse effects of flunitrazepam include dependency, both physical and psychological; reduced sleep quality resulting in somnolence; and overdose, resulting in excessive sedation, impairment of balance and speech, respiratory depression or coma, and possibly death. Because of the latter, flunitrazepam is commonly used in suicide among the elderly. When used in late pregnancy, it might cause hypotonia of the fetus.

Dependence

Flunitrazepam, as with other benzodiazepines, can lead to drug dependence.

Paradoxical effects

Flunitrazepam may cause a paradoxical reaction in some individuals, including anxiety, aggressiveness, agitation, confusion, disinhibition, loss of impulse control, talkativeness, violent behavior, and even convulsions. Paradoxical adverse effects may even lead to criminal behaviour.

Hypotonia

Benzodiazepines such as flunitrazepam are lipophilic and rapidly penetrate membranes and, therefore, rapidly cross over into the placenta with significant uptake of the drug. Use of benzodiazepines including flunitrazepam in late pregnancy, especially high doses, may result in hypotonia, also known as floppy baby syndrome.

Other

Flunitrazepam impairs cognitive functions. This may appear as lack of concentration, confusion and anterograde amnesia—the inability to create memories while under the influence. It can be described as a hangover-like effect which can persist to the next day. It also impairs psychomotor functions similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs; falls and hip fractures were frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments.

Other adverse effects include:

• Slurred speech
• Gastrointestinal disturbances, lasting 12 or more hours
• Vomiting
• Respiratory depression in higher doses

Special precautions

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or drug-dependent individuals, and in individuals with comorbid psychiatric disorders.

Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important adverse effect. This side-effect is not unique to flunitrazepam but also occurs with other hypnotic drugs. Flunitrazepam seems to have a particularly high risk of road traffic accidents compared to other hypnotic drugs. Extreme caution should be exercised by drivers after taking flunitrazepam.

Interactions

The use of flunitrazepam in combination with alcoholic beverages synergizes the adverse effects, and can lead to toxicity and death.

Overdose

Flunitrazepam is a drug that is frequently involved in drug intoxication, including overdose. Overdose of flunitrazepam may result in excessive sedation, or impairment of balance or speech. This may progress in severe overdoses to respiratory depression or coma and possibly death. The risk of overdose is increased if flunitrazepam is taken in combination with CNS depressants such as ethanol (alcohol) and opioids. Flunitrazepam overdose responds to the GABAA receptor antagonist flumazenil, which thus can be used as a treatment.

Detection

As of 2016, blood tests can identify flunitrazepam at concentrations of as low as 4 nanograms per millilitre; the elimination half-life of the drug is 4–12 hours. For urine samples, metabolites can be identified for 60 hours to 28 days, depending on the dose and analytical method used. Hair and saliva can also be analyzed; hair is useful when a long time has transpired since ingestion, and saliva for workplace drug tests.

Flunitrazepam can be measured in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or assist in a medicolegal death investigation. Blood or plasma flunitrazepam concentrations are usually in a range of 5–20 μg/L in persons receiving the drug therapeutically as a nighttime hypnotic, 10–50 μg/L in those arrested for impaired driving and 100–1000 μg/L in victims of acute fatal overdosage. Urine is often the preferred specimen for routine substance use monitoring purposes. The presence of 7-aminoflunitrazepam, a pharmacologically active metabolite and in vitro degradation product, is useful for confirmation of flunitrazepam ingestion. In postmortem specimens, the parent drug may have been entirely degraded over time to 7-aminoflunitrazepam. Other metabolites include desmethylflunitrazepam and 3-hydroxydesmethylflunitrazepam.

Pharmacology

The main pharmacological effects of flunitrazepam are the enhancement of GABA, an inhibitory neurotransmitter, at various GABA receptors. Negative ions such as chloride inhibit the ability of neurons to fire. It is this stimulation of GABA receptors which is responsible for the depressant effects of benzodiazepines. Flunitrazepam shows high affinity for the α-5 subunit of the GABA-A receptor, which causes some of its unique side effects, such as amnesia.

While 80% of flunitrazepam that is taken orally is absorbed, bioavailability in suppository form is closer to 50%.

Flunitrazepam has a long half-life of 18–26 hours, which means that flunitrazepam's effects after nighttime administration persist throughout the next day.

Flunitrazepam is lipophilic and is metabolised by the liver via oxidative pathways. The enzyme CYP3A4 is the main enzyme in its phase 1 metabolism in human liver microsomes.

Chemistry

Flunitrazepam is classed as a nitro-benzodiazepine. It is the fluorinated N-methyl derivative of nitrazepam. Other nitro-benzodiazepines include nitrazepam (the parent compound), nimetazepam (methylamino derivative) and clonazepam (2ʹ-chlorinated derivative).

Flunitrazepam has a melting point of around 170 degrees Celsius.

History

Flunitrazepam was discovered at Roche as part of the benzodiazepine work led by Leo Sternbach; the patent application was filed in 1960 and it was first marketed in 1972.

Due to use of the drug for date rape and recreation, in 1998 Roche modified the formulation to give lower doses, make it less soluble, and add a blue dye for easier detection in drinks. It was never marketed in the United States, and by 2016 had been withdrawn from the markets in Spain, France, Norway, Germany, and the United Kingdom.

Society and culture

Recreational and illegal uses

Recreational use

A 1989 article in the European Journal of Clinical Pharmacology reports that benzodiazepines accounted for 52% of prescription forgeries in Sweden, suggesting that benzodiazepines were a major prescription drug class of abuse. Nitrazepam accounted for 13% of forged prescriptions, and accounted for 44% of forgeries specifically for benzodiazepines while flunitrazepam, diazepam, and oxazepam accounted for the majority of the rest of benzodiazepine forgeries. Prescription forgeries for other benzodiazepines marketed in Sweden (alprazolam, clonazepam, lorazepam, clobazam, and bromazepam) were negligible. When calculated in relation to utilization, the narcotic analgesics codeine, pentazocine, and ketobemidone were at the top of the list for the highest number of overall prescription forgeries, suggesting a higher abuse potential of these drugs. In neighboring Finland, temazepam accounts for roughly 40–50% benzodiazepine prescription forgeries annually, while flunitrazepam accounts for approximately ~15% of benzodiazepine prescription forgeries.

Flunitrazepam and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other benzodiazepines and nonbenzodiazepines (anxiolytic or hypnotic) such as zolpidem and zopiclone (as well as cyclopyrrolones, imidazopyridines, and pyrazolopyrimidines) are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range, suggesting a high degree of potential for addiction for benzodiazepines and similar drugs.

Suicide

In studies in Sweden, flunitrazepam was the second most common drug used in suicides, being found in about 16% of cases. In a retrospective Swedish study of 1,587 deaths, in 159 cases benzodiazepines were found. In suicides when benzodiazepines were implicated, the benzodiazepines flunitrazepam and nitrazepam occurred in significantly higher concentrations compared to natural deaths. Of the 159 deaths where any benzodiazepines were found, 4 deaths were caused by benzodiazepines alone (in the other 155 cases, benzodiazepines were combined with something else). One conclusion of the study was that flunitrazepam and nitrazepam might be more toxic than other benzodiazepines available in the Swedish market.

Drug-facilitated sexual assault

Main article: Drug facilitated sexual assault

Flunitrazepam is known to induce anterograde amnesia in sufficient doses; individuals are unable to remember certain events that they experienced while under the influence of the drug, which complicates investigations. This effect could be particularly dangerous if flunitrazepam is used to aid in the commission of sexual assault; victims may be unable to clearly recall the assault, the assailant, or the events surrounding the assault.

While use of flunitrazepam in sexual assault has been prominent in the media, as of 2015 it appears to be fairly rare, and use of alcohol and other benzodiazepine drugs in date rape appears to be a larger but underreported problem.

In a 2001 study, the benzodiazepines midazolam and temazepam were the two most common benzodiazepines utilized for date rape.

Drug-facilitated robbery

In the United Kingdom, the use of flunitrazepam and other "date rape" drugs have also been connected to stealing from sedated victims. An activist quoted by a British newspaper estimated that up to 2,000 individuals are robbed each year after consuming drinks spiked with powerful sedatives, making drug-assisted robbery a more commonly reported problem than drug-assisted rape.

Regional use

Flunitrazepam is a Schedule III drug under the international Convention on Psychotropic Substances of 1971.

• In Australia, as of 2013 the drug was authorized for prescribing for severe cases of insomnia but was restricted as a Schedule 8 medicine.
• In France, as of 2016 flunitrazepam was not marketed.
• In Germany, as of 2016 flunitrazepam is an Anlage III Betäubungsmittel (controlled substance which is allowed to be marketed and prescribed by physicians under specific provisions) and is available on a special narcotic drug prescription as the Rohypnol 1 mg film-coated tablets and several generic preparations (November 2016).
• In Ireland, flunitrazepam is a Schedule 3 controlled substance with strict restrictions.
• In Japan, flunitrazepam is marketed by Japanese pharmaceutical company Chugai under the trade name Rohypnol and is indicated for the treatment of insomnia as well as used for preanesthetic medication.
• In Mexico, Rohypnol is legally available.
• In Norway, on January 1, 2003, flunitrazepam was moved up one level in the schedule of controlled drugs and, on August 1, 2004, the manufacturer Roche removed Rohypnol from the market there altogether.
• In South Africa, Rohypnol is classified as a Schedule 6 drug. It is available by prescription only, and restricted to 1 mg doses.

• In Iceland, flunitrazepam is a controlled substance available from Mylan. It is prescribed for severe insomnia and is sometimes used before surgery to induce a calm, relaxed state of mind for the patient.
• In Sweden, flunitrazepam is a List II drug (substances with medicinal uses) under the Narcotics Control Act (1968). It was previously available from Mylan, but has been removed from the market in January 2020.
• In the United Kingdom, flunitrazepam is not licensed for medical use and is a controlled drug under Schedule 3 and Class C.
• In the United States, the drug has not been approved by the Food and Drug Administration and is considered to be an illegal drug; as of 2016 it is Schedule IV. and provide for punishment for the importation and distribution of up to 20 years in prison and a fine; possession is punishable by three years and a fine. Travelers travelling into the United States are limited to a 30-day supply. The drug must be declared to US Customs upon arrival. If a valid prescription cannot be produced, the drug may be subject to Customs search and seizure, and the traveler may face criminal charges or deportation.

Names

Flunitrazepam is marketed under many brand names in the countries where it is legal. It also has many street names, including "roofie" and "ruffie".

References

References

1. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (2009). "Principles of addiction medicine". Wolters Kluwer/Lippincott Williams & Wilkins.
3. (November 2013). "Prescribing of Benzodiazepines Alprazolam and Flunitrazepam". New South Wales Health.
4. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
5. (June 2000). "Drug-facilitated sexual assault ('date rape')". Southern Medical Journal.
6. (2014-02-19). "Drug facilitated sexual assault: detection and stability of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry". PLOS ONE.
7. (November 1980). "Flunitrazepam: a review of its pharmacological properties and therapeutic use". Drugs.
8. (1976). "Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial". Acta Anaesthesiologica Scandinavica.
9. (2003). "The role of benzodiazepines in elderly suicides". SAGE Publications.
10. (April 1979). "Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines". JAMA.
11. (June 2006). "Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions". Forensic Science International.
12. (May 1982). "Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations". Drugs.
13. (2004). "Residual effects of hypnotics: epidemiology and clinical implications". CNS Drugs.
14. (August 2010). "Effect of hypnotic drugs on body balance and standing steadiness". Sleep Medicine Reviews.
15. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Annales Pharmaceutiques Françaises.
16. (December 2008). "Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam". Sleep Medicine.
17. (2014). "Guidance for healthcare professionals on drug driving". The Department for Transport.
18. (8 January 2015). "Benzodiazepines drug profile". European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
19. (2002). "[Analysis of benzodiazepine derivative mixture by gas-liquid chromatography]". Medicina.
20. (March 2002). "Citalopram in fatal poisoning cases". Forensic Science International.
21. (April 2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Therapeutic Drug Monitoring.
22. (January 1998). "Stability of nitrobenzodiazepines in postmortem blood". Journal of Forensic Sciences.
23. (2008). "Disposition of Toxic Drugs and Chemicals in Man". Biomedical Publications.
24. (October 13, 2022). "Flunitrazepam (Rohypnol) Fact Sheet & Harm Reduction Guide".
25. (1977). "Bioavailability from various galenic formulations of flunitrazepam". Arzneimittel-Forschung.
26. (2014). "Benzodiazepine pharmacology and central nervous system-mediated effects". The Ochsner Journal.
27. (February 2001). "CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam". Drug Metabolism and Disposition.
28. (May 1995). "Postmortem drug metabolism by bacteria". Journal of Forensic Sciences.
29. (1 May 1963). "Quinazolines and 1,4-Benzodiazepines. X.1 Nitro-Substituted 5-Phenyl-1,4-benzodiazepine Derivatives2". Journal of Medical Chemistry.
30. (2016). "Neuropathology of drug addictions and substance misuse. Volume 2, Stimulants, club and dissociative drugs, hallucinogens, steroids, inhalants, and international aspects". Academic Press.
31. (November 1989). "Use of prescription forgeries in a drug abuse surveillance network". European Journal of Clinical Pharmacology.
32. "Classification of controlled drugs". EMCDDA.
33. (April 2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Therapeutic Drug Monitoring.
34. (January 2000). "Among fatal poisonings dextropropoxyphene predominates in younger people, antidepressants in the middle aged and sedatives in the elderly". Journal of Forensic Sciences.
35. (November 1993). "[Benzodiazepine findings in autopsy material. A study shows interacting factors in fatal cases]". Läkartidningen.
36. (September 1993). "Deaths involving the benzodiazepine flunitrazepam". The American Journal of Forensic Medicine and Pathology.
37. (3 June 1999). "Bankrånare stärkte sig med Rohypnol?". DrugNews.
38. "Mijailovic var påverkad av våldsdrog". Expressen.
39. (2001). "Benzodiazepines and GHB". Humana Press.
40. (December 19, 2004). "'Rape drug' used to rob thousands". The Guardian.
41. (2015). "List of Psychotropic Substances under International Control". International Narcotics Control Board.
42. (August 13, 2004). "Authorisation to Supply or Prescribe Drugs of Addiction: Flunitrazepam". Department of Health, Government of Western Australia.
43. "Flunitrazepam - Anwendung, Wirkung, Nebenwirkungen". Vidal MMI Germany GmbH.
44. (1993). "S.I. No. 342/1993 — Misuse of Drugs (Amendment) Regulations". Irish Statute Book, Statutory Instruments.
45. (October 2015). "Kusuri-no-Shiori Drug Information Sheet". RAD-AR Council, Japan.
46. (May 27, 2019). "What is Rohypnol?".
47. (February 2006). "[Changes in the sale and use of flunitrazepam in Norway after 1999]". Tidsskrift for den Norske Laegeforening.
48. (October 11, 2006). "Rohypnol". Drug Wars – About Drugs.
49. "Flunitrazepam Mylan".
50. "Flunitrazepam". Medical Products Agency.
51. "Substans". Farmaceutiska Specialiteter i Sverige (FASS) Allmänhet.
52. "Flunitrazepam utgår". Janusinfo.
53. (8 August 2022). "List of most commonly encountered drugs currently controlled under the misuse of drugs legislation". Gov.uk.
54. DEA [Lists of Scheduling Actions Controlled Substances Regulated Chemicals May 2016]
55. (29 October 2013). "Flunitrazepam (Rohypnol)". University of Maryland.
56. "International brands for Flunitrazepam". Drugs.com.